BiotechTube

HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Genital Herpes

Conditions

Genital Herpes

Trial Timeline

Feb 18, 2020 → May 19, 2021

NCT ID
NCT04222985

About HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%

HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9% is a phase 1 stage product being developed by Merck for Genital Herpes. The current trial status is terminated. This product is registered under clinical trial identifier NCT04222985. Target conditions include Genital Herpes.

What happened to similar drugs?

10 of 20 similar drugs in Genital Herpes were approved

Approved (10) Terminated (0) Active (10)
✅Risankizumab + Placebo for RisankizumabAbbVieApproved
✅Famciclovir + PlaceboNovartisApproved
✅FamciclovirNovartisApproved
✅FamciclovirNovartisApproved
✅turoctocog alfaNovo NordiskApproved
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved
✅activated recombinant human factor VIINovo NordiskApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04222985Phase 1Terminated

Competing Products

20 competing products in Genital Herpes

See all competitors
ProductCompanyStageHype Score
mRNA-1608ModernaPhase 2
0
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
Fulvestrant + AbemaciclibEli LillyPhase 2
39
EDIT-101Editas MedicinePhase 1/2
18
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
ASP2151 + PlaceboAstellas PharmaPhase 1
29
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Topical NO + PlaceboKyowa KirinPhase 2
35
KW-3357Kyowa KirinPhase 1
29
Ixekizumab + PlaceboEli LillyPhase 3
40
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
40
DaratumumabJohnson & JohnsonPhase 2
27